James A. Posey
Thomas Jefferson University · 122 works · 7,830 citations · h-index 33
Top works
- Hepatobiliary Cancers
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- Esophageal and Esophagogastric Junction Cancers, Version 1.2015
- Gastric Cancer, Version 2.2013
- Esophageal and Esophagogastric Junction Cancers
- A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
- A Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α v β 3 ) Antibody in Patients with Metastatic Cancer
- Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
- A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)
- Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity
- Gastric Cancer
- A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
- NCCN Practice Guidelines for Colorectal Cancer.
- Hepatobiliary Cancers, Version 2.2014
- Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
- Predictive Capacity of Three Comorbidity Indices in Estimating Mortality After Surgery for Colon Cancer
- Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas
- Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin (DOX) in chemotherapy-naïve, unresectable hepatocellular carcinoma (HCC)
- Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer